Purpose <p>Spinal cord stimulation (SCS) is a surgical intervention for patients with neuropathic pain refractory to medical management. There are limited data on its outcomes from Canadian centres. We aimed to describe the indications, patient- and procedure-related characteristics, and outcomes of patients who underwent SCS implantation at a Canadian tertiary centre.</p> Methods <p>We conducted a retrospective cohort study of patients who underwent SCS at St. Michael’s Hospital (Toronto, ON, Canada) between 1 January 2020 and 31 July 2023. We collected data on patient demographics, analgesic use, type of SCS trial (percutaneous <i>vs</i> tunneled), indication, antibiotic use during and after surgery, and complications.</p> Results <p>We included 100 patients with a mean (standard deviation) age of 62 (14) yr. Indications included chronic pain after spinal surgery (<i>n</i> = 44), chronic back pain (no prior spine surgery) (<i>n</i> = 22), complex regional pain syndrome (<i>n</i> = 6), spinal stenosis (<i>n</i> = 4), and visceral pain (<i>n</i> = 4). Complications included implantable pulse generator-associated pain (47%), lead migration (14%), lead fracture (9%), surgical site infection (2%), and cerebrospinal fluid leak (6%). Almost all patients were on pharmacotherapy for pain relief at baseline (<i>n</i> = 96) and agents included opioids, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antidepressants.</p> Conclusions <p>In this cohort of patients who underwent SCS implantation at a Canadian tertiary centre, infection and lead migration rates were consistent with global estimates (3.8% and up to 27%, respectively); nevertheless, we observed high rates of dural puncture compared with an expected incidence of 0.48%.</p>